PubMed Health⌕ Search

PubMed · 11970640

Different statistical mechanical ensembles for a stretched polymer.

Abstract

Imposing to a single polymer chain of N monomers either a fixed pair of forces +/-f acting at the chain ends (stress ensemble) or a fixed end-to-end vector R (strain ensemble) does correspond to the use of different statistical mechanical ensembles. In particular, the two elasticity laws, R(f)=g(f) and f(R)=h(R), where R(f) is the length of the average end-to-end vector (f) in the stress ensemble and f(R) is the intensity of the average internal force (R) in the strain ensemble, are not equivalent. For these conjugated ensembles, the quantity Delta(f)=f-h(g(f)) and more generally Delta(O)= (f)- (R) where O is an arbitrary observable, is studied systematically in this paper for a wide class of polymer models corresponding to chains at temperatures equal or above the theta point. The leading term Delta((2))(O) of an expansion of Delta(O) in terms of the successive moments of the end-to-end vector fluctuations in the stress ensemble can be used to analyze the scaling properties of Delta(f). For the Gaussian and the freely jointed chain models, Delta(O) proportional to 1/N for large N with the particularity that, for the elasticity law, Delta(f) strictly vanishes for the Gaussian chain at any finite N. For chains in good solvent, the usual result Delta(f) proportional to 1/N at fixed f is only valid in the highly stretched chain regime (Pincus regime). N independent large ensemble differences of the order of 20% on Delta(f) are noticed when the chain is stretched over a distance of the order of the unstretched chain average end-to-end distance R0. These effects decrease to the 1% level for R(f)>3R(0). Monte Carlo calculations for a chain model containing both excluded volume and finite extensibility features illustrate the distinction between the elasticity laws in the two ensembles over all stretching regimes. Our study suggests that the nature of the constraints used in single chain micromanipulations could be relevant to the interpretation of experimental elasticity law data.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J T Titantah, C Pierleoni, J P Ryckaert. 1999. Different statistical mechanical ensembles for a stretched polymer.. https://doi.org/10.1103/physreve.60.7010

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗